Endometriosis Market Key Highlights:
- Market Size (2024): USD 1,544 Million
- Projected Market Size (2034): USD 1,792 Million
- CAGR (2023-2034): 1.5%
Pricing Analysis:
- Price Growth
- Regional Variations
Market Historic Sales
- Total sales volume, year-over-year growth, product categories, and market share.
Revenue Estimation
- Forecasting future revenues based on historical data, market trends, and economic indicators.
Sales by Region
- Breakdown of sales performance across different geographical areas.
Revenue by Manufacturer
- Analysis of revenue contributions from different manufacturers in the market.
Endometriosis Market Definition
The endometriosis market is an important sector of the pharmaceutical industry. This industry deals in the manufacturing and distribution of endometriosis-curing therapies across the world. There are different types of treatment provided by this industry that generally include pain medication and hormone therapy. Endometriosis therapies are distributed by a suitable supply chain consisting of hospital pharmacies, retail pharmacies, and others. This market is expected to rise significantly with the growth in the healthcare industry across the world.
The growing prevalence of endometriosis among women across the world has increased the demand for effective therapies for cure, thereby driving the market expansion. Also, the rising use of oral contraceptives and NSAIDs for treating uterus dysfunctions, along with increased use of gonadotropin-releasing hormone for uterus protection, has contributed positively to the industrial expansion. Moreover, the availability of endometriosis therapies in various administration routes, such as oral, injectables, and some others, is expected to propel the growth of the endometriosis market.
The advancements in nanomedicines along with development in pelvic floor physiotherapy and non-hormonal treatment are expected to create ample growth opportunities for the market players in the future. In August 2022, Pfizer announced that the FDA approved MYFEMBREE. MYFEMBREE is an effective therapy used for treating endometriosis.
Endometriosis Market Segmentation:
By Type
- Gonadotropins Releasing Hormone Agonists
- Non-Steroidal Anti-Inflammatory Drugs
- Progestin
- Oral Contraceptive Pills
By Application
- Hospital Use
- Clinic Use
- Other
Endometriosis Market Companies:
- AbbVie
- AstraZeneca
- Bayer HealthCare
- Pfizer
- Addex Therapeutics
- Astellas Pharma
- Debiopharm
- ElexoPharm
- EndoCeutics
- Euroscreen
- Forendo Pharma
- Kissei Pharmaceutical
- Neurocrine Biosciences
- Nippon Shinyaku
- Takeda
- Bayer AG
- Neurocrine Biosciences.
For any questions about this dataset or to discuss customization options, please write to us at sales@statifacts.com
